

The Board's proposal for mandate to issue new shares (item 16 on the agenda)

The Board of Infant Bacterial Therapeutics AB, org.nr 556873-8586, proposes that the Meeting authorize the Board, on one or more occasions until the next AGM, to decide on the issuance of Class B shares ("shares"). Board to decide to issue shares in deviation from the shareholders.

As for the issue of shares with deviation from the shareholders (private placements), the Directors are not able to make decisions means that the share capital be increased by more than twenty (20) percent in relation to the share capital which exists when the share issue authorization is first put into claims of a private placement.

The issue under this authorization shall be on market terms. The Board shall have the right to determine the conditions in the rest of the issues under this authorization and who should have the right to subscribe for shares. The reason for the Board to decide on share issue with deviation from shareholders' preferential rights is to conduct private placements in order to obtain capital for the company.

The President proposed to be authorized to make minor adjustments to this resolution that may be necessary in connection with registration with the Swedish Companies Registration Office and Euroclear Sweden AB.

A resolution in accordance with the Board's proposal requires approval of shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting.